Table 1

Baseline characteristics of participants

 PlaceboZoledronate
n=50n=50
Age, years56 (11)56 (12)
Male, n (%)46 (92)47 (94)
Ethnicity, n (%)
Pacific19 (38)23 (46)
European21 (42)15 (30)
Māori9 (18)9 (18)
Other1 (2)3 (6)
Age of first episode, years32 (13)36 (14)
Disease duration, years24 (11)20 (10)
Number of gout flares in preceding 3 months1.92 (2.78)2.19 (2.93)
On urate-lowering therapy, n (%)43 (86)48 (96)
Colchicine use, n (%)30 (60)23 (46)
Prednisone use, n (%)12 (24)7 (14)
Non-steroidal anti-inflammatory drug use, n (%)28 (56)31 (62)
Diuretic use, n (%)5 (10)4 (8)
Number of subcutaneous tophi7.9 (6.5)6.6 (7.6)
Tender joint count3.58 (10.83)3.16 (8.25)
Swollen joint count1.30 (5.44)0.40 (1.73)
Grip strength, kg33.4 (13.1)31.2 (14.6)
HAQ-II0.51 (0.61)0.65 (0.66)
Patient global assessment20.0 (26.0)18.2 (25.0)
Pain score, mm10.8 (20.0)15.9 (27.0)
Serum urate, mmol/L0.37 (0.11)0.38 (0.13)
Serum creatinine, μmol/L97.3 (20.6)97.2 (24.5)
Procollagen-1 N-terminal propeptide (P1NP), μg/L56.9 (28.4)56.8 (37.8)
Serum β-CTX, ng/mL0.31 (0.16)0.28 (0.16)
Urine CTX-II, ng/mmol326 (399)407 (390)
BMD spine, g/cm21.36 (0.18)1.34 (0.21)
BMD total hip, g/cm21.13 (0.15)1.12 (0.17)
BMD total body, g/cm21.32 (0.10)1.32 (0.14)
BMD T-score spine1.18 (1.49)1.01 (1.76)
BMD T-score total hip0.24 (1.04)0.15 (1.2)
BMD T-score total body1.33 (1.23)1.38 (1.67)
CT erosion score17.7 (11.8)16.4 (13.0)
XR damage score (erosion and joint space narrowing)49.4 (53.8)52.2 (53.7)
XR erosion score32.0 (36.3)37.0 (37.0)
  • Unless stated, data are presented as mean (SD).

  • BMD, bone mineral density; β-CTX, β-C-terminal telopeptide of type I collagen; CTX-II: C-terminal telopeptide of type II collagen; HAQ, Health Assessment Questionnaire; XR: plain radiography.